Myeloid-Lymphoid Leukemia Protein
"Myeloid-Lymphoid Leukemia Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
| Descriptor ID |
D051788
|
| MeSH Number(s) |
D12.776.260.560 D12.776.624.664.700.148 D12.776.930.483
|
| Concept/Terms |
Myeloid-Lymphoid Leukemia Protein- Myeloid-Lymphoid Leukemia Protein
- Myeloid Lymphoid Leukemia Protein
- Zinc Finger Protein HRX
- MLL Proto-Oncogene Protein
- MLL Proto Oncogene Protein
- Proto-Oncogene Protein, MLL
- Proto-Oncogene Proteins MLL
- MLL, Proto-Oncogene Proteins
- Proto Oncogene Proteins MLL
- Acute Lymphoblastic Leukemia Protein 1
- Mixed-Lineage Leukemia Protein
- Mixed Lineage Leukemia Protein
|
Below are MeSH descriptors whose meaning is more general than "Myeloid-Lymphoid Leukemia Protein".
Below are MeSH descriptors whose meaning is more specific than "Myeloid-Lymphoid Leukemia Protein".
This graph shows the total number of publications written about "Myeloid-Lymphoid Leukemia Protein" by people in this website by year, and whether "Myeloid-Lymphoid Leukemia Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 4 | 2 | 6 |
| 2011 | 0 | 1 | 1 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 2 | 3 |
| 2014 | 5 | 2 | 7 |
| 2015 | 2 | 1 | 3 |
| 2016 | 5 | 2 | 7 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 5 | 1 | 6 |
| 2021 | 3 | 1 | 4 |
| 2022 | 6 | 3 | 9 |
| 2023 | 1 | 1 | 2 |
| 2024 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid-Lymphoid Leukemia Protein" by people in Profiles.
-
MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024 Oct 29; 15(1):9341.
-
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol. 2024 Oct 04; 7(1):1257.
-
Identification of single-cell blasts in pediatric acute myeloid leukemia using an autoencoder. Life Sci Alliance. 2024 Nov; 7(11).
-
Histone H3K18 & H3K23 acetylation directs establishment of MLL-mediated H3K4 methylation. J Biol Chem. 2024 Aug; 300(8):107527.
-
Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia. Pediatr Blood Cancer. 2024 Jun; 71(6):e30964.
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 01 01; 109(1):293-297.
-
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023 04 13; 13(1):53.
-
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol. 2023 04; 98(4):E91-E94.
-
IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. EMBO Mol Med. 2023 01 11; 15(1):e15631.
-
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022 11; 36(11):2729-2733.